Daisy Wolf speaks with Dr. Andrew Huberman, professor of neurobiology and ophthalmology at Stanford University and host of the Huberman Lab podcast. They discuss how the pandemic sparked a consumer health revolution, the emerging peptide and GLP landscape, what the science actually says about focus drugs, and the neurotechnologies Huberman believes will let us write to our own biology within the next five years.

Resources:

Follow Andrew Huberman on X: https://twitter.com/hubermanlab

Follow Daisy Wolf on X: https://twitter.com/daisydwolf

Stay Updated:

If you enjoyed this episode, be sure to like, subscribe, and share with your friends!

Find a16z on X: https://twitter.com/a16z

Find a16z on LinkedIn: https://www.linkedin.com/company/a16z

Listen to the a16z Show on Spotify: https://open.spotify.com/show/5bC65RDvs3oxnLyqqvkUYX

Listen to the a16z Show on Apple Podcasts: https://podcasts.apple.com/us/podcast/a16z-podcast/id842818711

Follow our host: https://x.com/eriktorenberg

Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see http://a16z.com/disclosures.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

a16z Partners Daisy Wolf and Eva Steinman talk with Zach Cohen and Raymond Wang, cofounders of Ease Health, a company building an AI operating system for behavioral health that combines CRM, EHR, and revenue cycle management into a single platform. They discuss why behavioral health software has lagged behind, what it means to build AI native versus AI integrated, and why Zach left his job as an investor at a16z to go build in this space. They also cover how Ease plans to replace the dozen software vendors most practices rely on today.

Resources:

Follow Daisy Wolf on X: https://x.com/daisydwolf

Follow Eva Steinman on LinkedIn: https://www.linkedin.com/in/eva-steinman/

Follow Zach Cohen on X: https://x.com/zachcohen25

Follow Raymond Wang on LinkedIn: https://www.linkedin.com/in/arrays/

Stay Updated:

If you enjoyed this episode, be sure to like, subscribe, and share with your friends!

Find a16z on X:https://x.com/a16z

Find a16z on LinkedIn: https://www.linkedin.com/company/a16z

Listen to the a16z Podcast on Spotify: https://open.spotify.com/show/5bC65RDvs3oxnLyqqvkUYX

Listen to the a16z Podcast on Apple Podcasts: https://podcasts.apple.com/us/podcast/a16z-podcast/id842818711

Follow our host: https://x.com/eriktorenberg

Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see http://a16z.com/disclosures

.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

At the Oliver Wyman Health Innovation Summit 2025, Julie Yoo, General Partner at a16z Bio + Health, makes the case that healthcare is uniquely positioned to benefit from AI more than any other industry. She argues that healthcare's historical underinvestment in technology is now an asset, enabling the industry to leapfrog directly to AI-native models of care delivery with unprecedented speed and scale.

Resources:

Follow Julie Yoo on X: https://x.com/julesyoo

Stay Updated:

If you enjoyed this episode, be sure to like, subscribe, and share with your friends!

Find a16z on X: https://twitter.com/a16z

Find a16z on LinkedIn: https://www.linkedin.com/company/a16z

Listen to the a16z Show on Spotify: https://open.spotify.com/show/5bC65RDvs3oxnLyqqvkUYX

Listen to the a16z Show on Apple Podcasts: https://podcasts.apple.com/us/podcast/a16z-podcast/id842818711

Follow our host: https://x.com/eriktorenberg

Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see http://a16z.com/disclosures

.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

a16z general partner Julie Yoo talks with Nikhil Buduma, CEO and cofounder of Ambience Healthcare, to discuss how AI is transforming clinical workflows. They cover the early days of deep learning, why Ambience started by running a medical practice before building a platform company, and what it takes to achieve high clinician adoption rates at major academic medical centers. They also dig into the challenge of building products when AI capabilities change every few months, the real ROI that's finally converting CFOs, and why this might be the moment to reimagine the legacy EHR stack.

Resources:

Follow Nikhil Buduma on X: https://twitter.com/nkbuduma

Follow Julie Yoo on X: https://twitter.com/julesyoo

Read the full transcript here: https://www.a16z.news/s/podcast

Stay Updated:

If you enjoyed this episode, be sure to like, subscribe, and share with your friends!

Find a16z on X: https://twitter.com/a16z

Find a16z on LinkedIn: https://www.linkedin.com/company/a16z

Listen to the a16z Show on Spotify: https://open.spotify.com/show/5bC65RDvs3oxnLyqqvkUYX

Listen to the a16z Show on Apple Podcasts: https://podcasts.apple.com/us/podcast/a16z-podcast/id842818711

Follow our host: https://x.com/eriktorenberg

Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see http://a16z.com/disclosures

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

a16z investors Daisy Wolf and Eva Steinman talk with Bobby Samuels, cofounder and CEO of Protege. They discuss the myth that we've run out of data for AI, how Protege connects healthcare systems and other data holders with the major AI labs, and why real-world data beats synthetic data for training models. Bobby also covers the growing demand for eval datasets, expanding beyond healthcare into video and audio, and what he's seeing from the biggest AI companies as they race to acquire training data.

Stay Updated:

If you enjoyed this episode, be sure to like, subscribe, and share with your friends!

Find a16z on X: https://twitter.com/a16z

Find a16z on LinkedIn: https://www.linkedin.com/company/a16z

Listen to the a16z Podcast on Spotify: https://open.spotify.com/show/5bC65RDvs3oxnLyqqvkUYX

Listen to the a16z Podcast on Apple Podcasts: https://podcasts.apple.com/us/podcast/a16z-podcast/id842818711

Follow our host: https://x.com/eriktorenberg

Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see http://a16z.com/disclosures.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Recently, a16z Bio + Health general partner Julie Yoo spoke with Nikita Singareddy, cofounder of Fortuna, and Florian Otto, cofounder of Cedar. They talked about why healthcare affordability is reaching a breaking point, how AI voice agents are transforming patient financial experiences, and what it will take to leapfrog decades of administrative burden in Medicaid—from 30-page paper applications to legacy technology systems built in the 1990s to the real opportunity for giving every American a "five-star healthcare experience."

Resources:

Follow Julie Yoo on X: https://twitter.com/julesyoo

Follow Nikita Singareddy on X: https://twitter.com/singareddynm

Check out Fortuna: https://www.fortunahealth.com/

Follow Florian Otto on X: https://twitter.com/flottobrasil

Check out Cedar: https://www.cedar.com/

Stay Updated:

If you enjoyed this episode, be sure to like, subscribe, and share with your friends!

Find a16z on X: https://twitter.com/a16z

Find a16z on LinkedIn: https://www.linkedin.com/company/a16z

Listen to the a16z Podcast on Spotify: https://open.spotify.com/show/5bC65RDvs3oxnLyqqvkUYX

Listen to the a16z Podcast on Apple Podcasts: https://podcasts.apple.com/us/podcast/a16z-podcast/id842818711

Follow our host: https://x.com/eriktorenberg

Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see http://a16z.com/disclosures.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Out-of-Pocket is a healthcare education company founded by Nikhil Krishnan that helps people understand how healthcare works and how to navigate it in practice. In this episode, a16z investing partner Jay Rughani and Nikhil discuss why health insurance is losing its role as the default way people access care. They explain how rising costs are pushing more consumers to pay out of pocket for diagnostics, preventive care, and navigation. The conversation also looks at what this shift means for startups, AI-powered tools, regulation, and access as healthcare continues to move beyond insurance.

Resources:

Follow Jay Rughani on X: https://twitter.com/JayRughani

Follow Nikhil Krishnan on X: https://twitter.com/nikillinit

Read Out of Pocket’s 2026 Predictions: https://www.outofpocket.health/p/out-of-pockets-2026-predictions

Stay Updated:

If you enjoyed this episode, be sure to like, subscribe, and share with your friends!

Find a16z on X: https://x.com/a16z

Find a16z on LinkedIn: https://www.linkedin.com/company/a16z

Listen to the a16z Podcast on Spotify: https://open.spotify.com/show/5bC65RDvs3oxnLyqqvkUYX

Listen to the a16z Podcast on Apple Podcasts: https://podcasts.apple.com/us/podcast/a16z-podcast/id842818711

Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details, please see http://a16z.com/disclosures

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Cofounders Jeremy Wohlwend and Gabriele Corso join the a16z podcast to discuss the launch of Boltz, a public benefit company building AI infrastructure for molecular biology. The conversation explains how breakthroughs following AlphaFold moved the field beyond protein structure prediction into modeling biomolecular interactions and binding strength, why open-source Boltz models saw rapid adoption across pharma and biotech, and how that work is now being productized. They outline the launch of Boltz Lab, a platform that brings protein and small-molecule design agents into scientist workflows, Boltz’s decision to operate as an infrastructure company rather than a therapeutics company, and how AI could reduce early drug discovery bottlenecks by improving molecular design and speeding iteration between computation and the lab.

Resources:

Follow Gabriele on X: https://twitter.com/GabriCorso

Follow Jeremy on X: https://twitter.com/jeremyWohlwend

Follow Jorge X: https://twitter.com/jorgecondebio

Follow Zak on X: https://twitter.com/zakdoric

Stay Updated:

If you enjoyed this episode, be sure to like, subscribe, and share with your friends!

Find a16z on X:https://twitter.com/a16z

Find a16z on LinkedIn: https://www.linkedin.com/company/a16z

Listen to the a16z Podcast on Spotify: https://open.spotify.com/show/5bC65RDvs3oxnLyqqvkUYX

Listen to the a16z Podcast on Apple Podcasts: https://podcasts.apple.com/us/podcast/a16z-podcast/id842818711

Follow our host: https://twitter.com/eriktorenberg](https://x.com/eriktorenberg

Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.